Spironolactone-Induced Hyperchloremic Acidosis in Cirrhosis

Publisher Website
Google Scholar
Abstract
Patients [6] with alcoholic cirrhosis developed a reversible metabolic acidosis during treatment with the aldosterone antagonist spironolactone. Mean serum bicarbonate concentration decreased significantly with spironolactone therapy (100-200 mg/day) from 18.2 .+-. 4.5 to 10.9 .+-. 3.2 med[equivalents]/l (P < 0.001). Upon withdrawal of spironolactone, serum bicarbonate concentration increased from 10.9 .+-. 3.2 to 18.1 .+-. 3.5 meq/l (P < 0.001). During the development of this hyperchloremic metabolic acidosis, serum K concentration rose from 3.7 .+-. 0.5 to 5.0 .+-. 0.8 meq/l (P < 0.005); this reversed after cessation of spironolactone therapy. These effects of spironolactone treatment were not associated with significant alterations in serum creatinine or Na concentration. Even though an aldosterone antagonist in the treatment of Na and H2O retention in cirrhotic patients may prevent hypokalemia and rapid diuresis, it may also induce or worsen another complication.sbd.hyperchloremic metabolic acidosis.

This publication has 19 references indexed in Scilit: